QYJD Compound Preparation Promotes Rapid Postoperative Recovery in Early-stage NSCLC Patients by Regulating Tissue Microecology: a Prospective, Randomized Controlled, Open-label, Phase I Clinical Study With Predefined Future Exploration

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 8, 2021

Primary Completion Date

December 8, 2022

Study Completion Date

December 8, 2023

Conditions
NSCLC
Interventions
DRUG

QYJD Compound Preparation

The intervention group was treated with 2 capsules (g) of expelling stasis and QYJD compound preparation orally for 4 days before thoracoscopic radical surgery for lung cancer, 3 times a day. The blank control group had no oral drug treatment before surgery.

Trial Locations (1)

350025

Zongyang Yu, Fujian

All Listed Sponsors
lead

Fuzhou General Hospital

OTHER